Strategic Partnerships Novilytic has established collaborations with Purdue Research Foundation and disclosed a finalist status in BioTools Innovator's 2025 competition, signaling active engagement with academic and industry ecosystems that can be leveraged for co-development, licensing, and pilot programs.

Proteometer Advantage The Proteometer platform consolidates multi-instrument, multi-person workflows into a single-user kit for titer, aggregates, and charge-variant analysis, presenting a compelling value proposition for labs seeking reduced labor, streamlined operations, and faster decision cycles.

Funding & Growth With NIH SBIR funding support and a seed round, combined with revenue in the mid five-figures to mid six-figures range, Novilytic demonstrates a viable growth trajectory and potential for expanded capital-enabled pilots and scale-up opportunities.

Academic & Lab Target Partnering with research institutions and biopharma-adjacent labs is a clear pathway, given the company’s emphasis on protein-quality insights and molecular recognition, suggesting opportunities for trials within university cores and contract research organizations.

Competitive Positioning Comparable peers operate in a similar segment with modest headcount but notable revenue; Novilytic can differentiate by highlighting lab efficiency gains, risk reduction in protein analysis, and a turnkey solution that reduces reliance on multiple instruments and specialized personnel.